Announced details
Treatment of chronic idiopathic thrombocytopenic purpura
トーアエイヨー is our consolidated subsidiary. The relationship with Fuji Pharma Co.,Ltd. is that Fuji Pharma Co.,Ltd. holds the marketing authorization and ensures stable supply, while トーアエイヨー handles sales and provides information to medical institutions.
Fuji Pharma Co.,Ltd.: Head office in Chiyoda-ku, Tokyo; Representative Director and President Morita Shuhei (森田周平). トーアエイヨー株式会社: Head office in Chuo-ku, Tokyo; Representative Director and President Ide Masahiko (出野将彦). Business activities, capital and year of establishment: not disclosed.
Eltrombopag Tablets 12.5 mg “F”: ¥924.10 per tablet. Eltrombopag Tablets 25 mg “F”: ¥1,833.20 per tablet.
The company does not address Contract Value / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Eltrombopag Tablets 12.5 mg “F”, Eltrombopag Tablets 25 mg “F” |
| Counterparty | Fuji Pharma Co.,Ltd., トーアエイヨー株式会社 |
| Counterparty overview | Fuji Pharma Co.,Ltd.: Head office in Chiyoda-ku, Tokyo; Representative Director and President Morita Shuhei (森田周平). トーアエイヨー株式会社: Head office in Chuo-ku, Tokyo; Representative Director and President Ide Masahiko (出野将彦). Business activities, capital and year of establishment: not disclosed. |
| Relationship with the Company | トーアエイヨー is our consolidated subsidiary. The relationship with Fuji Pharma Co.,Ltd. is that Fuji Pharma Co.,Ltd. holds the marketing authorization and ensures stable supply, while トーアエイヨー handles sales and provides information to medical institutions. |
| Offering price | Eltrombopag Tablets 12.5 mg “F”: ¥924.10 per tablet. Eltrombopag Tablets 25 mg “F”: ¥1,833.20 per tablet. |
| Launch date | 12 June 2026 (actual; launched on the same day) |
| Applicable area | Treatment of chronic idiopathic thrombocytopenic purpura |
Items this document does not state (11)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The two companies stated that the arrangement is intended to contribute to patients’ health and well-being in line with their respective corporate philosophies.